HAMBURG, Germany--(BUSINESS WIRE)--Mindpeak, the leader in AI-powered pathological solutions, today announced it has raised $15.3 million in a Series A funding round. The round was led by ZEISS Ventures and InnoVentureFund with participation from - amongst others - AI.FUND and the European Innovation Council Fund.

德国汉堡--（商业新闻短讯）--人工智能驱动的病理学解决方案的领导者Mindpeak今天宣布，它已在a轮融资中筹集了1530万美元。这一轮由蔡司风险投资公司（ZeissVentures）和创新创业基金（InnoVentureFund）牵头，AI.FUND和欧洲创新委员会基金（European Innovation Council FUND）等机构参与。

While Mindpeak has a cash-flow positive core business, this new investment will enable the company to further expand the commercialisation of its pioneering technologies across several geographies..

虽然Mindpeak的核心业务现金流为正，但这项新投资将使该公司能够在多个地区进一步扩大其领先技术的商业化。

'With this new capital, we will accelerate the development and deployment of our AI solutions, empowering pathologists and researchers with faster, more accurate diagnostic tools,' said Felix Faber, CEO of Mindpeak. 'Our goal is to revolutionize cancer diagnostics and ultimately improve patient outcomes.'.

Mindpeak首席执行官费利克斯·费伯（FelixFaber）说：“有了这笔新资金，我们将加快人工智能解决方案的开发和部署，为病理学家和研究人员提供更快、更准确的诊断工具。”我们的目标是彻底改变癌症诊断并最终改善患者预后。”

Mindpeak’s AI algorithms were among the first to be deployed for routine clinical diagnostics in both the US and EU. The company’s innovative solutions enable automated histological and immunohistochemical tissue analysis, helping experts make more confident decisions. To date, over 30,000 patient diagnoses have been supported using the AI solution.

Mindpeak的人工智能算法是美国和欧盟首批用于常规临床诊断的算法之一。该公司的创新解决方案可实现自动组织学和免疫组织化学分析，帮助专家做出更有信心的决定。迄今为止，已经使用AI解决方案支持了30000多例患者诊断。

“Since its founding in 2018, Mindpeak has developed cutting-edge solutions, establishing itself as a prominent leader in the digital pathology market,” said Mike Gänßler, Investment Manager at ZEISS Ventures. “Both as an investor and as a market partner, we are firmly convinced of Mindpeak’s promising future.'.

蔡司风险投资公司投资经理迈克·甘勒（MikeGänßler）表示：“自2018年成立以来，Mindpeak开发了尖端解决方案，成为数字病理市场的杰出领导者。“无论是作为投资者还是作为市场合作伙伴，我们都坚信Mindpeak充满希望的未来。”

Recently, Mindpeak expanded its product portfolio to include additional organs, biomarkers, and stainings. Strategic partnerships with leading healthcare organizations, such as Roche, along with positive regulatory developments, further bolster the company’s position in the market.

最近，Mindpeak扩大了其产品组合，包括其他器官，生物标志物和染色。与罗氏（Roche）等领先医疗保健组织的战略合作伙伴关系，以及积极的监管发展，进一步巩固了公司在市场上的地位。

'Mindpeak’s commitment to innovation in digital pathology has been evident through their rapid product development and growing adoption across markets,' said Gencer Sahin, Head of Investments at IFB Innovationsstarter GmbH / InnoVentureFund. “This funding round will further solidify their position as a key player in the transformation of cancer diagnostics.'.

。“这轮融资将进一步巩固他们在癌症诊断转型中的关键角色地位。”

About Mindpeak

关于Mindpeak

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care.

Mindpeak成立于2018年，是人工智能驱动的数字病理学解决方案的全球创新者。该公司开发了支持病理学家进行常规诊断的尖端算法，专注于自动化组织分析以获得更快，更准确的结果。Mindpeak的平台旨在提高临床实验室的生产力和诊断信心，帮助改善癌症护理中的患者预后。

For more information, visit www.mindpeak.ai, Twitter, and LinkedIn..

有关更多信息，请访问www.mindpeak.ai、Twitter和LinkedIn。

About ZEISS Ventures

关于蔡司风险投资

ZEISS Ventures, the corporate venture capital arm of the ZEISS Group, makes investments and actively manages a portfolio of startup companies. Our goal is to invest in and partner with deep-tech startups, which go beyond ZEISS' core business and have the potential to disrupt and innovate existing technologies and business models.

蔡司风险投资公司是蔡司集团的企业风险投资子公司，负责投资并积极管理初创公司的投资组合。我们的目标是投资深度科技初创公司并与之合作，这些公司超越了蔡司的核心业务，有可能颠覆和创新现有的技术和商业模式。

ZEISS Ventures aims to provide startups not only with the capital they need, but also with access to its resources, capabilities, and global network as a deep-tech corporation in order to foster and accelerate their development. For more information, visit www.zeiss.com/ventures..

蔡司风险投资公司的目标不仅是为初创企业提供所需的资金，而且还可以作为一家深度技术公司获得其资源、能力和全球网络，以促进和加速其发展。

About IFB Innovationsstarter / InnoVentureFund

关于InnoVentureFund的IFB创新发起人

InnoVentureFund invests in young innovative companies in order to strengthen the Hamburg start-up scene and to support startups in their further growth. Investments up to a maximum of EUR 7.0 million per company are possible together with private investors. 70% of the funds come from the federal government via KfW and 30% from the Free and Hanseatic City of Hamburg.

InnoVentureFund投资于年轻的创新型公司，以加强汉堡的创业环境，并支持初创公司的进一步发展。与私人投资者一起，每家公司最多可投资700万欧元。70%的资金来自联邦政府通过KfW，30%来自汉堡自由汉萨城。

The fund is managed by IFB Innovationsstarter, a wholly owned subsidiary of Hamburgische Investitions- und Förderbank. More information can be found at www.innovationsstarter.com..

。有关更多信息，请访问www.innovationsstarter.com。

About AI.FUND

关于AI.FUND

AI.FUND is an AI specialized, entrepreneurial venture capital fund investing in future European AI champions to promote impactful AI made in Europe. The fund invests into highly scalable AI driven businesses in the early growth stage across various verticals and horizontals sectors.

AI.FUND是一家人工智能专业创业风险投资基金，投资于未来的欧洲人工智能冠军，以推广欧洲制造的有影响力的人工智能。该基金在各个纵向和横向部门的早期增长阶段投资于高度可扩展的人工智能驱动的业务。